Skip to main content
Lilly's biomarker-driven therapy for HCC approved by FDA

Eli Lilly and Co.'s Cyramza, or ramucirumab, gained FDA approval as a monotherapy for hepatocellular carcinoma in patients with alpha-fetoprotein levels of 400 nanograms per milliliter or higher who were previously treated with sorafenib. Cyramza is the first biomarker-driven therapy approved by the FDA as an HCC treatment.

Full Story: